Kiniksa Pharmaceuticals International, plc
KNSA
Classement en actions
#2915
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prix de l'action
$80.10
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$6.25B
Changement (1 jour)
-3.69%
Changement (1 an)
105.92%
Pays
GB
Échange Kiniksa Pharmaceuticals International, plc (KNSA)
Catégorie
Healthcare
Historique du prix de l'action pour Kiniksa Pharmaceuticals International, plc (KNSA)
Prix de clôture le plus élevé : $78.59 le 2026-10-01
Prix de clôture le plus bas : $18.08 le 2018-05-01
Prix de clôture le plus bas : $18.08 le 2018-05-01
Historique du prix de l'action de Kiniksa Pharmaceuticals International, plc de 2018 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 31.83% |
| 2025 | 101.55% |
| 2024 | 16.14% |
| 2023 | 13.98% |
| 2022 | 22.63% |
| 2021 | -31.53% |
| 2020 | 57.49% |
| 2019 | -47.95% |
| 2018 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.48 | 35.42% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.52 | -0.48% |
IT
|
